p53 missense mutant proteins commonly show increased stability compared to wild-type p53, which is thought to depend largely on the inability of mutant p53 to induce the ubiquitin ligase MDM2. However, recent work using mouse models has shown that the accumulation of mutant p53 occurs only in tumour cells, indicating that stabilization requires additional factors. To clarify the stabilization of p53 mutants in tumours, we analysed factors that affect their folding and degradation. Although all missense mutants that we studied are more stable than wild-type p53, the levels correlate with individual structural characteristics, which may be reflected in different gainof-function properties. In the absence of Hsp90 activity, the less stable unfolded p53 mutants preferentially associate in a complex with Hsp70 and CHIP (carboxy terminus of Hsp70-interacting protein), and we show that CHIP is responsible for ubiquitination and degradation of these mutants. The demonstration of a complex interplay between Hsp90, Hsp70 and CHIP that regulate the stability of different p53 mutant proteins improves our understanding of the pro-tumorigenic effects of increased Hsp90 activity during multi-stage carcinogenesis. Understanding the roles of Hsp90, Hsp70 and CHIP in cancers may also provide an important avenue through which to target p53 to enhance treatment of human cancers.
Introduction
Mutations of p53 generally result in the inactivation of its tumour-suppressor functions, and the role of different p53 mutants in cancer progression is associated either with wild-type independent oncogenic gain of function or with trans-dominant suppression of wildtype p53. While most tumour suppressor genes are inactivated either by mutations leading to absence of protein or by production of truncated protein product, the majority of mutations found in TP53 gene (Blagosklonny et al., 1995) result in single amino-acid substitutions. These missense mutations take place in the DNA-binding core domain of p53, producing a fulllength protein that is incapable of binding DNA and is therefore nonfunctional as a transcriptional activator/ repressor. One of the most interesting aspects of mutant p53 proteins is their structural, biochemical and biological heterogeneity. The mutations in the core region, found in human tumours, have been classified based on thermodynamic stability and DNA-binding properties. The contact mutants with changes in residues that are directly involved in binding DNA (such as 248R or 273R) have little effect on protein folding or stability. However, the majority of mutations cause local distortion, mainly in proximity to the DNA-binding site (for example, R249S) or can cause global unfolding (for example, mutation in the b-sandwich, for example, V157F) (Bullock and Fersht, 2001) .
The level of p53 protein is mainly regulated at the post-translational level by the MDM2 protein, while expression of MDM2 is activated by p53 at the transcription level, forming a negative feedback loop to maintain p53 protein at low levels under normal conditions (Barak et al., 1993; Wu et al., 1993) . This feedback loop does not necessarily involve only MDM2, as other ligases were found to be responsible for degradation of p53 protein. Furthermore, different mechanisms were described to stabilize wild-type p53 protein, including inhibitors of transcription inducing stabilization of wild-type p53 via initial inhibition of MDM2 and p21 WAF1 (Blagosklonny, 2004) . Stabilization of mutated p53 in tumours is mostly ascribed to lack of induction of MDM2 by mutant p53, although recent genetic models have suggested that this is an oversimplification because mice engineered to express mutant p53 protein either with or without the wild-type allele show high levels of protein expression only in tumour tissue and not in normal tissue (Lang et al., 2004 ).
An additional factor responsible for regulating the stability of p53 is interaction with molecular chaperones, including Hsp70 and Hsp90 (Hinds et al., 1987; Selkirk et al., 1994) . It was also shown that binding of Hsp90 to p53 inhibits the ability of MDM2 to promote p53 ubiquitination and degradation, resulting in the stabilization of both mutant p53 and MDM2 (Nagata et al., 1999; Peng et al., 2001a, b) . Although MDM2 plays a central role in proteasomal targeting of p53, additional ubiquitin ligases participate in normal cells, including p300, Pirh2, COP1 and CHIP (carboxy terminus of Hsp70-interacting protein) (Grossman et al., 2003; Leng et al., 2003; Dornan et al., 2004; Esser et al., 2005) . Esser et al. (2004) have identified a pathway for protein degradation that involves close cooperation of the molecular chaperones Hsp70 and Hsp90 with the ubiquitin-proteasome system. The major influence on this degradation pathway is mediated by the chaperoneassociated ubiquitin ligase CHIP (Ballinger et al., 1999) . In our study, we have extended these initial observations and investigated the role of these chaperones in folding and stabilization of p53 mutants with different properties. We demonstrate a major role for CHIP ubiquitin ligase in the degradation of unfolded p53 mutants, with little or no roles for CHIP in degrading wild-type or mutant p53 proteins that adopt a folded conformation.
Results

Correlation of p53 level with conformation and impact of Hsp90
We analysed the folding of different p53 mutants using conformational-specific monoclonal antibodies. We simultaneously analysed the role of Hsp90 in mutant p53 folding using 17AAG to inhibit Hsp90 activity (Figure 1 ). In cells bearing the mutations E285K, R175H and R156P, we detect only denatured conformation of p53 (PAb240-positive) in both untreated and 17AAG-treated cells, while cells with mutation at codons R273H, R280K, R249S and L194F contain both native (PAb1620-positive) and denatured conformation of p53 (PAb240-positive). Inhibition of Hsp90 by 17AAG leads to reduced levels of folded (PAb1620-positive) p53 in these cells, indicating the essential role of Hsp90 in folding these mutant proteins to adopt a partially native conformation.
To correlate the stabilization of mutant p53 protein with conformation, the level of p53 was measured using two-site ELISA (Figure 2a ) and western blotting (Figure 2b ) of the same lysate. Figure 2a represents the relative level of p53 proteins, captured with DO-1 monoclonal antibody and detected with CM1 polyclonal sera, and was normalized to the total protein concentration in cell lysates. All mutants are present at higher levels than the wild-type protein in MCF-7 cells. However, the protein levels of mutants that display predominantly well-folded proteins (PAb1620-positive) are particularly high compared with proteins that adopt a predominantly denatured conformation. These results indicate that the unfolded mutant p53 proteins that do not rely on Hsp90 activity are less stable than folded mutant p53 proteins that require Hsp90 activity, to achieve their final conformation.
Negligible role of MDM2 in degradation of p53 mutants
To evaluate the importance of MDM2 in mutant p53 degradation, cells were treated with Nutlin-3 that specifically inhibits the interaction between p53 and Figure 1 Conformation of mutated p53. Immunoprecipitation of p53 with PAb1620 and PAb240 was used to assess the folding status of p53. Cells were treated with Hsp90 inhibitor 17AAG (4 mM) for 12 h. Immunoprecipitated p53 was detected by CM1 antibody and the band intensity was measured by densitometry. Bar graph shows the ratio of folded (PAb1620-positive, black) and unfolded (PAb240-positive, grey) p53. 100% is the sum of band densities of p53 precipitated by PAb1620 and PAb240 antibody. This graph approximately reflects the ratio of folded and unfolded protein.
Stabilization and degradation of p53 mutants P Muller et al MDM2. Figure 3 shows the results for cell lines that contain mixtures of folded and denatured p53 (MDA-MB-231 and T47D) or only denatured p53 (HOS).
Complexes were demonstrated in all cells using immunoprecipitation for p53 followed by western blotting for MDM2. The p53-MDM2 interaction was disrupted by treatment with Nutlin-3 in all cell lines, as expected ( Figure 3 ). However, Nutlin-3 has no effect on p53 levels in these cells, indicating the inability of MDM2 to degrade both native and denatured conformations of mutant p53. To further define the role of MDM2 in ubiquitination and degradation of p53, we used Nutlin-3 treatment after Hsp90 inhibition with 17AAG
( Figures 4a and b ). Inhibiting Hsp90 with 17AAG causes variable degrees of degradation of p53 mutants and a minimal effect on wild-type p53 in MCF-7 cells. Nutlin-3 caused a progressive stabilization of wild-type p53 after Hsp90 inhibition. In contrast, mutant p53 was not progressively stabilized but remained susceptible to degradation after Nutlin-3 and 17AAG treatment ( Figure 4a) . Thus, the decrease in mutant p53 stability seen after inhibition of Hsp90 activity is not dependent on MDM2. This result also identified the lower stability of unfolded mutants in comparison with folded mutants (folded mutants are marked by *). To quantify the Figure 4b shows the time required for the p53 level to decay to half of its initial value. In addition, we used the inducible stable transfected hotspot mutant p53 R175H (typical unfolded mutant) and mutant p53 R273H (fully-folded mutant) to show that the unfolded mutants exhibit distinctively longer halflife in the same cellular background ( Figure 5 and Supplementary data 2).
Effect of 17AAG on ubiquitination of p53 mutants
The above data are in agreement with the findings of Blagosklonny et al. (1995) that geldanamycin specifically affects mutated but not wild-type p53, indicating that mutant p53 is degraded when Hsp90 is inhibited. To investigate the role of ubiquitination in Hsp90-mediated degradation of different p53 mutants, cells were treated with 17AAG and/or proteasome inhibitor MG-132. Simultaneous treatment by Nutlin-3 was also used to investigate MDM2 independent ubiquitination. Ubiquitination of wild-type p53 protein in MCF-7 cells requires MDM2 to interact with p53, seen by the lack of ubiquitination in the presence of Nutlin-3 ( Figure 6a ). Hsp90 inhibition has only a marginal effect on ubiquitination of wild-type p53. On the other hand, denatured mutants E285K, R249S, R175H and R156P are ubiquitinated independently of both Hsp90 and MDM2, whereas naturally folded mutants R273H and R280K require 17AAG treatment for ubiquitination and L194F ubiquitination is enhanced by 17AAG. As with the denatured mutants, MDM2 is not involved in ubiquitination of naturally folded mutant p53 proteins.
To exclude a possible role of different genetic backgrounds in our panel of cell lines that might reflect intrinsic differences in MDM2, Hsp90 or other activities, p53-null H1299 cells were used to analyse the conformational status and degradation of two major p53 mutants, R175H and R273H, that are expressed in SKBR3 and MDA-MB-468 cells, respectively. Identical results were obtained with the mutants expressed in H1299 cells as were seen in the original cell lines, indicating that it is the intrinsic nature of the mutation that regulates stability and ubiquitination, not differences in the cellular background (data not shown). Thus, ubiquitination of mutant p53 molecules that adopt a native conformation is highly sensitive to inhibition of Hsp90 activity, whereas ubiquitination of unfolded p53 mutants occurs in the absence of Hsp90 activity.
We also used p53À/À MDM2À/À mouse embryonic fibroblasts (MEFs) to prove that p53 mutant degradation is not dependent on MDM2 but is related to Hsp90 activity. p53À/À MDM2À/À MEFs were transfected with human mutant p53 R175H and treated by chemically unrelated inhibitors of Hsp90 17AAG, radicicol and novobiocin. Figure 6b shows that inhibition of Hsp90 causes a decrease in the levels of this mutant protein and the additional inhibition of proteasome activity by MG-132 confirms that this mutant is ubiquitinated in the absence of active Hsp90.
Interaction of unfolded p53 and Hsp70/Hsc70
Cell line MDA-MB-468 bearing p53 R273H mutation was employed to test the interaction of Hsp70 with p53. This mutant exhibits structural stability comparable to wild-type p53 protein and its degradation is not influenced by MDM2 (Figure 6a ). Combined treatment with 17AAG and MG-132 at either 37 or 39 1C was applied to investigate the link between structural stability of p53, its folding and degradation. Immunoprecipitation with PAb1620 shows that mutant p53 R273H protein is folded and highly expressed at both temperatures ( Figure 7 ). 17AAG treatment, responsible for elevation of unfolded p53 protein fraction, is associated with a slight degradation at 39 1C. Treatment with MG-132 shows that mutant p53 R273H is ubiquitinated to a higher degree at both 37 and 39 1C after inhibition of Hsp90 with 17AAG. These results support the idea that unfolded p53 protein is destined for rapid degradation. Altogether, inhibition of Hsp90, inhibition of proteasome and higher temperature increase the ratio between the unfolded and folded p53 fraction.
We were unable to detect complex formation between p53 and Hsp70 under physiological conditions at 37 1C. Stable complex formation was detected either after inactivation of Hsp90 activity with 17AAG or during The interaction between Hsp70 and mutant p53 was further analysed after temperature shift to 39 1C. We found that this interaction is characterized by recruitment of inducible form of Hsp70 (Hsc70) not only following higher temperature exposure but also after 17AAG treatment.
CHIP is responsible for degradation of unfolded p53
The above data show that Hsp70 specifically interacts with unfolded mutant p53 and targets it for degradation, suggesting the possible role of Hsp70-associated ubiquitin ligase CHIP in this process. To analyse the ability of CHIP to degrade unfolded p53, full-length or truncated isoforms of CHIP lacking the U-Box domain were Figure 4 Time-dependent degradation of p53 mutants after 17AAG and Nutlin-3 treatment. Equal numbers of cells were treated with 4 mM 17AAG or with 4 mM 17AAG and 10 mM Nutlin-3 and harvested at various times. The level of p53 was detected using western blotting and antibody DO-1. Folded mutants are labelled by '*' (a). The immunoblots were analysed by densitometry; the column graph (b) shows the half-life of p53 after 17AAG treatment. Full regression analysis is presented in Supplementary data 1A-H. (X) No data were obtained, because the level of wild-type p53 is increased after Nutlin-3 treatment.
Stabilization and degradation of p53 mutants P Muller et al transiently transfected in to H1299-175 cells expressing unfolded p53 R175H mutant (Figure 8 ). Our data confirmed the ability of full-length CHIP to degrade mutant p53 R175H, with higher degradation rate in the presence of 17AAG (Figure 8a ). Transfection of truncated 200AA CHIP lacking U-Box region did not destabilize unfolded p53 mutant, but attenuated the effect of 17AAG on p53 degradation. These data demonstrate the requirement of both TRP and U-Box domain for degradation of unfolded p53 mutants. Similar data were obtained using H1299-273 cells. Flow cytometry was additionally used to quantify the effect of CHIP on the level of mutant p53 R175H (Figure 8b and Supplementary data 3). Full-length CHIP markedly decreased the level of p53 in transfected cells, whereas the truncated 200AA CHIP had the opposite effect, indicating that this form of CHIP is responsible for the increase of p53 level but is also capable in blocking the effect of inhibition of Hsp90 by 17AAG.
CHIP forms a complex with Hsp70 and ubiquitinates bound p53
The immunoprecipitation of a complex between Hsp70, p53 and CHIP was performed to clearly demonstrate the mechanism of p53 ubiquitination by CHIP. Figure 9 shows that full-length CHIP induces ubiquitination of p53 R273H and the effect is enhanced if the folding is blocked by 17AAG. The dominant negative 200AA CHIP is unable to induce ubiquitination of p53 even though it forms a stable complex with Hsp70 and p53. The relatively higher stability of the complex with truncated 200AA CHIP underlines the temporal character of the less stable complex formed by fulllength CHIP, which results in ubiquitination and degradation of denatured p53. The fact that the protein complex between p53, Hsp70 and CHIP is assembled especially after Hsp90 inhibition emphasizes the role of CHIP in the degradation of unfolded p53.
Discussion
The aim of our study has been to elucidate the role of Hsp90 and other chaperones in folding and stabilization of different p53 mutants. Regulation of stability of unfolded p53 protein is mediated through Hsp90, so it precedes negative feedback loop regulation and results in either folding or degradation of p53. Our work shows that increased Hsp90 activity and the preference of folding is another important condition for expression of high levels of mutant p53. This finding can explain why mouse models that inherit homozygous p53 mutations express the mutant p53 protein at low levels in differentiated tissues (Lang et al., 2004) . Therefore, alterations of the balance of folding/degradation can be responsible for tumour-specific stabilization of mutant p53.
We show that p53 mutants adopting mainly unfolded conformations are associated with lower protein levels, implying that these p53 mutants exhibit higher levels of degradation. These mutants require inhibition of Hsp90 for ubiquitination, whereas ubiquitination of other hotspot mutants proceeds in the absence of Hsp90 activity. We also showed that unfolded p53 mutants interact with Hsp70, and that CHIP can induce degradation of these mutants. The data suggest that ubiquitination of mutant p53 is a consequence of its denaturation and interaction Stabilization and degradation of p53 mutants P Muller et al with Hsp70, leading to CHIP-mediated ubiquitination and proteasomal degradation. Many p53 mutants responsible for transformation display structural defects and associate with the molecular chaperones Hsc70 and Hsp90 in tissue culture cells and human tumours (Soussi and Lozano, 2005) . We showed that increased temperature and/or inhibition of Hsp90 by 17AAG lead to an elevation in the fraction of denatured p53 in tumour cells. Our data also show that Hsp90 is responsible for proper folding of p53 or forms a stable complex with mutants that adopt unfolded conformations. Therefore, the activity of Hsp90 and its relationship with Hsp70 and other cochaperones are crucial factors that determine stabilization or degradation of newly synthesized proteins, depending on the precise mutation and the effect on Figure 6 (a) MDM2-independent ubiquitination of p53 mutants. Cells were treated with 4 mM 17AAG to inhibit Hsp90 and to increase p53 unfolded fraction. Proteasome inhibitor MG-132 (20 mM) was used to inhibit degradation of ubiquitinated p53. Nutlin-3 (10 mM) was used to disclose the role of MDM2 in the ubiquitination process. (b) p53À/À MDMÀ/À MEFs were transfected with human p53 R175H and treated with 4 mM 17AAG, 4 mM radicicol, 10 mM novobiocin and MG-132 (20 mM). (* mostly folded mutants).
Stabilization and degradation of p53 mutants P Muller et al p53 conformation. In particular, conformationally unfolded p53 mutants form a complex with Hsc70 and are addressed to degradation by CHIP if Hsp90 activity is low. Temperature shift to 39 1C further augments this effect, both by induction of CHIP and Hsp70 homologues and also by further destabilization of p53 structure. Although all p53 missense mutants studied here exhibit increased stability compared to wild-type, a quantitative analysis and comparison with different conformation-specific antibodies show for the first time that proteins that adopt a native conformation are particularly stable. Experiments performed in transfected H1299 cells indicate that these differences are not due to different cellular backgrounds. In human tumours, the level of mutant p53 detected by immunohistochemistry shows a broad range (Nenutil et al., 2005) , suggesting that specific mutation site may be one factor that influences the overall level of p53 in primary human tumours. The model explaining the longer halflife and higher expression of folded mutants is described in Supplementary data 4.
The inherent stability and dominant gain-of-function properties of mutant p53 protein in tumours have been questioned by the analysis of p53 in knock-in p53 mice (Lang et al., 2004; Olive et al., 2004) . Levels of p53 R172H and R270H are very low in normal tissues and are stabilized only in some cancers in these mice, indicating that other cellular factors are involved in tumour-specific stabilization (Lang et al., 2004; Olive et al., 2004; Soussi and Lozano, 2005) . One possibility is that p53 modifications such as acetylation or phosphorylation are responsible for this tumour-specific stabilization (Lang et al., 2004; Olive et al., 2004) . However, because Hsp90 exists in cancer cells in a highly activated state, susceptible to bind to its inhibitor 17AAG approximately 100 times more tightly compared with Hsp90 expressed in normal cells (Kamal et al., 2003; Workman, 2004) , our data provide an additional explanation for tumour-specific stabilization by protecting against interaction with Hsp70 and CHIP. The level of this unfolded protein can then reflect differences in chaperone constitution in normal and cancer cells, where assembly of multichaperone complexes and high Hsp90 activity will stabilize mutated p53 in cancer. The relationship between p53 mutants and Hsp90 activity is further supported by the recent demonstration that Hsp90b coding gene repression is mediated by wild-type p53 (Zhang et al., 2004) , suggesting that the development of p53 mutation and increased Hsp90 activity can be coincident processes in tumorigenesis. These factors may also influence the ability of mutant p53 to exhibit dominant effects. In general, proteins that adopt only the denatured conformation are less stable and, therefore, may be less effective in inhibiting wild-type p53 functions, which may also help to explain the different tumorigenic properties observed for different mutations Figure 7 Analysis of p53 R273 H conformation and its interaction with Hsp70. MDA-MB-468 cells containing folded p53 R273H were treated for 8 h at 37 or 39 1C. Cells were treated with 4 mM 17AAG (inhibition of Hsp90) and with 20 mM MG-132 (proteasome inhibition). The level of Hsp90, Hsp70 and p53 was detected using western blotting. Conformational changes of p53 were assessed using immunoprecipitation with conformation-specific monoclonal antibodies PAb1620 and PAb240. Complexes between p53 and Hsp70 were analysed using immunoprecipitation of p53 with rabbit polyclonal antibody CM1.
Stabilization and degradation of p53 mutants P Muller et al Stabilization and degradation of p53 mutants P Muller et al expressed in heterozygous mutant mice (Olive et al., 2004 ). An alternative proposal that post-translational modifications may be required for mutant p53 to inhibit wild-type p53 (Lang et al., 2004) is not supported by the findings that p53 phosphorylation does not correlate with transcriptional activity in primary human breast, ovary and cervix tumours (Nenutil et al., 2005) . It was shown earlier that the loss of p53 transfunction is sufficient for its stabilization without any change in conformation (Blagosklonny, 2004) . Moreover, we found that mutant p53 proteins exhibiting wild-type conformation are expressed at higher levels. Our data indicate that unfolded p53 mutant proteins interact with Hsp70 and are hence available for CHIPmediated degradation. This finding is also in agreement with the theoretical prediction that degradation of p53 mutant is not associated with MDM2 feedback loop (Blagosklonny, 1997) . Higher expression of folded p53 mutants was also observed in knock-in mouse models bearing either folded or unfolded p53 mutants (Jackson et al., 2005) . Chaperone-mediated degradation of p53 may also be involved in other drug-induced degradation of p53 mutants. Besides geldanamycin analogues, several groups of drugs were found to influence the ability of Hsp90 to fold its client proteins. Different histone deacetylase (HDAC) inhibitors (such as FK228, LAQ824 or LBH589) were also found to be able to inhibit Hsp90 and alter the function of Hsp70 Wang et al., 2007) . Accordingly, the inhibition of Hsp90 by HDAC inhibitors may be involved in depletion of mutant p53 caused by trichostatin A or FR901228 treatment (Blagosklonny et al., 2005) . Furthermore, it was shown that HDAC inhibitors potentiate their anti-tumour effect with 17AAG and promote proteasomal degradation of Hsp90 clients such as Bcr-Abl (Nimmanapalli et al., 2003; George et al., 2005) .
In summary, we found that Hsp90 plays a key role in the folding of p53 mutants with native conformation. The levels of denatured p53 mutants are generally lower than natively folded p53 mutants and the Hsp90 inhibitor 17AAG decreases the level of denatured p53 mutants, indicating that Hsp90 prevents degradation of denatured p53 mutants. Surprisingly, MDM2 is unable to ubiquitinate p53 mutants even though it forms stable complexes, leaving space for the function of other ubiquitin ligases such as CHIP. Our model showing the balance between folding and degradation of p53 by CHIP is described in Figure 10 . The relevancy of cooperation between heat-shock proteins and p53 for In addition, our data indicate that manipulating CHIP activity in cells may prove useful for the treatment of tumours that bear specific types of p53 mutation. In this respect, careful characterization of the ability of Hsp90, Hsp70 and CHIP to regulate p53 stability and conformation will be necessary for the development of therapies that are designed to interfere with mutant p53 activities in tumours.
Materials and methods
Cell culture and treatment Human cancer cell lines HOS, BT474, MDA-MB-468, MDA-MB-231, T47D, BT549 and SKBR3 contain different p53 mutations (R156P, E285K, R273H, R280K, L194F, R249S and R175H, respectively), whereas the wild-type allele was lost in all these cell lines. MCF-7 cells contain wild-type p53, and H1299 cells are p53-null. Cell lines H1299-neo, H1299-175 and H1299-273 were developed by stable transfection of empty pcDNA3 vector or pcDNA3 containing the p53 hot-spot mutants R175H and R273H, respectively. MEFs from p53À/À MDM2À/À mice were generously provided by Dr G Lozano (Lang et al., 2004) . Cells were cultured in D-MEM, 10% fetal bovine serum, 300 mg l À1 L-glutamine and penicillin/ streptomycin. Cells were grown to 80% confluence before experimental treatments. 17AAG (17-(allylamino)-17-demethoxygeldanamycin), Nutlin-3 and MG-132 were added to a final concentration of 2-20 mM.
Antibodies
We used the following anti-p53 antibodies for immunoprecipitation (1 mg per reaction) or western blotting (1 mg ml
À1
): monoclonal antibody DO-1 recognizing the N-terminus of the protein (Vojtesek et al., 1992) , Bp53-10 monoclonal antibody recognizing the C-terminus of the protein (Bartek et al., 1993) , PAb1620 monoclonal antibody directed towards the wild-type conformation of human p53 protein (Milner, 1997; Wang et al., 2001) , PAb240 monoclonal antibody directed towards the mutant conformations of p53 (Gannon et al., 1990) and CM1 rabbit polyclonal antibody. MDM2 was detected by monoclonal antibody 2A9 (Chen et al., 1993) , Hsp90 by monoclonal antibody AC88 (StressGen, Canada), and Hsp70 and Flag epitope by in-house mouse monoclonal antibodies.
ELISA assay
A sandwich immunoassay to measure the level of p53 protein in total cell extracts was performed as described . The immunoassay was performed using monoclonal antibody DO-1 as the solid-phase reagent and polyclonal rabbit antiserum CM-1 to detect the captured protein. ELISA was quantified using linear regression of the relationship between optical density and total protein concentration (quantifying specific antibody concentrations by enzyme-linked immunosorbent assay using slope correction) (Barrette et al., 2006) .
Immunoblotting and immunoprecipitation
Treated and control cells were collected by centrifugation, washed three times with ice-cold PBS and lysed in 150 mM Figure 10 Folding-degradation balance of the p53 protein. Native or denatured p53 protein is bound by Hsp70 (I). In collaboration with other co-chaperones, the unfolded p53 is sent to the next processing. Especially HOP (II) helps to link Hsp70 substrate to Hsp90 and enables the folding of p53 by Hsp90 Zylicz et al., 2001) . Naturally unfolded mutants, such as p53 R175H, form stable complex with chaperones and Hsp90 activity is crucial to prevent their degradation (III). If the Hsp90 activity is lower or blocked by 17AAG (IV), the denatured mutants bind complex Hsp70 and CHIP (V). Tetratricorepeat (TPR) domain of CHIP binds the C terminus of Hsp70 and the U-box domain is responsible for ubiquitination of unfolded p53. The ubiqutinated p53 protein is degraded in proteasome (VI). NaCl; 50 mM TrisCl, pH 8.0; 5 mM EDTA; 1% NP-40; 1 mM PMSF buffer supplemented with protease inhibitor cocktail (Sigma-Aldrich, Inc., USA). A 20 mg portion of total proteins was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 10 or 12.5% gels and transferred onto nitrocellulose membranes. Membranes were blocked in 5% milk and 0.1% Tween 20 in PBS and probed overnight with specific monoclonal antibodies or rabbit polyclonal sera. To confirm equal protein loading, immunodetection was performed with the anti-actin AC-40 monoclonal antibody. Peroxidase-conjugated rabbit anti-mouse immunoglobulin or swine anti-rabbit immunoglobulin antisera (DAKO Ltd., Denmark) were used as the secondary antibodies and visualized with ECL reagents from Amersham-Pharmacia (Little Chalfont, England).
Immunoprecipitation of conformationally different forms of p53 protein was performed by using 1 mg of mouse monoclonal antibodies DO-1, PAb240 or PAb1620, as described previously (Gannon et al., 1990; Milner, 1997) . For co-immunoprecipitation of p53 complexes, cells were lysed in 150 mM NaCl, 50 mM HEPES (pH 7.2) and 0.5% Tween 20 and sonicated. Cell lysate (200 ml) containing 200-800 mg of total protein was incubated with 2 mg of appropriate antibody. A 15 ml volume of protein G-conjugated magnetic beads (Dynal, Norway) was used to precipitate the antibody. After three washes in lysis buffer, beads were resuspended in 60 ml of 2 Â concentrated Laemmli buffer. For electrophoresis, 8 ml of samples were used.
Constructs CHIP cDNA was amplified using total RNA and one-step RT-PCR with primers 5 0 -CTTAAGAGCGCGGGGACAGG-3 0 and 5 0 -ACAGATAGTGGCGGCAATGG-3 0 . Nested forward primer 5 0 -gacaGGTACCATGGATTACAAGGATGACGAC GATAAGaagggcaaggaggagaaggag-3 0 containing N-terminal Flag (italics) and KpnI restriction site (underlined) and reverse primers 5 0 -tctgGAATTCtcagtagtcctccacccagcc-3 0 or 5 0 -tctgGAATTCctagtacttgtcgtgcttggcctc-3 0 containing EcoRI restriction site (underlined) and stop codon (italics) were used for amplification and cloning of full-length and truncated CHIP into pcDNA3 vector. p53 mutants R175H and R273H were expressed in pCDNA3 plasmid. Inducible p53 mutants R175H and R273H were cloned using gateway (Invitrogen) into pEGSH FRT GW, a newly constructed plasmid containing ecdysone-inducible promoter and FRT recombination site (Supplementary data 2B). The plasmids PERV3 (Stratagene Inc., USA) and pFRT/lacZeo (Invitrogen Corp., USA) were used to make stable isogenic, ecdysone-inducible cell line H1299-PERV3 lacZeo3. The plasmid pOG44 (Invitrogen Corp., USA) containing Flp recombinase was used for recombination.
Transfection and FLP recombination 10 6 H1299 cells were transfected with 2 mg of plasmid DNA in nucleofector Kit-C solution using program X-005 (Amaxa GmbH, Germamy). Transfection efficiency was evaluated using pmaxGFP. Cells were treated and harvested 36 h after transfection. H1299 cells intended for stable integration of p53 mutants were treated with geneticin G418 (3 mg ml À1 ). Stable clones forming colonies were selected within 4 weeks and tested for p53 expression. The Flp-In system (Invitrogen Corp., USA) was used to make integration of different p53 mutants in H1299 cells at a specific genomic location. H1299 cells were transfected by pFRT/lacZeo construct to generate clones containing single FRT site for Flp-mediated recombination. Clones were selected by Zeocin (100 mg ml À1 ) and were tested for lacZ activity. The correct integration of single copy of the pFRT/lacZeo construct was tested by Southern blotting and real-time PCR of genomic DNA. Selected clone H1299 lac Zeo was than stably transfected with PERV3 construct (Stratagene Inc., USA) to produce clones expressing modified ecdysone receptor VgEcR and transcription co-activator RXR. The clones were selected by geneticin G418 (3 mg ml À1 ) and were tested for expression of VgEcR and RXR by anti-VP-16 anti RXR monoclonal antibody (Santa Cruz Biotechnology, USA; sc-7545 and sc-46659). The resultant clone, called H1229-PERV3 laczeo3, was used for integration of the construct pEGSH FRT containing ecdysone-inducible promoter and either mutant p53 R175H or mutant p53 R273H. The recombination of the p53 mutant constructs was facilitated by transient transfection of pOG44 expressing Flp recombinase. Successfully recombined clones containing correctly integrated pEGSH p53 R175H or R273H were selected with 500 mg ml
À1
Hygromycin (recombination is schematically presented in Supplementary data 2A).
